80
Participants
Start Date
October 12, 2017
Primary Completion Date
January 25, 2022
Study Completion Date
January 25, 2022
Tesevatinib
Pharmaceutical form: Tablet; Route of administration: orally
Placebo
Pharmaceutical form: Tablet (identical to tesevatinib); Route of administration: orally
Baylor Scott & White Research Institute, Temple
Rogosin Institute, New York
University of Pennsylvania, Philadelphia
University of Maryland, Baltimore
University of Virginia, Charlottesville
Emory University School of Medicine, Atlanta
Genesis Clinical Research, Tampa
Coastal Nephrology Associates Research Center, LLC, Port Charlotte
Medical College of Wisconsin, Milwaukee
Mayo Clinic, Rochester
Washington University, St Louis
University of Colorado Denver, Aurora
University of California Los Angeles, Los Angeles
California Institute for Renal Research, La Mesa
University of California San Diego, La Jolla
University of California San Francisco, San Francisco
Yale Nephrology Clinical Research, New Haven
Tufts Medical Center, Boston
Beth Israel Deaconess Medical Center, Boston
Kadmon, a Sanofi Company
INDUSTRY